MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.esmoop.2026.108578

Медицинская библиотека · ESMO open · 2026

Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial.

Nakamura Y, Esaki T, Nishina T, Shinozaki E, Taniguchi H, Kato T, Komatsu Y, Yuki S, Kato K, Wakabayashi M, Ikeno T, Ishiguro Y, Takahashi K, Ikeda Y, Asano M, Sato A, Kuwata T, Yoshino T

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Tissue-based tumor mutational burden (TMB) is a biomarker for immune checkpoint inhibitors; however, data on circulating tumor DNA (ctDNA)-based blood TMB (bTMB) are limited.

PATIENTS AND

METHODS

We conducted an amended phase II basket study enrolling patients with gastrointestinal (GI) cancers with high bTMB identified using Guardant360® CDx (cohorts 1 and 2) and patients with GI cancers with ultrahigh bTMB identified using Guardant360® CDx (Ultrahigh TMB GI cohort; top 2% within each GI tumor type). After early discontinuation of the Ultrahigh TMB GI cohort, the bTMB-High cohort enrolled patients with solid tumors across cancer types with bTMB score ≥14, as measured by FoundationOne® Liquid CDx. Nivolumab 360 mg was administered intravenously every 3 weeks until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) and hypothesis testing was prespecified for the bTMB-High cohort.

RESULTS

Seventy patients were treated (cohort 1, n = 28; cohort 2, n = 4; Ultrahigh TMB GI cohort, n = 19; bTMB-High cohort, n = 19). The ORR was 14.3%, 0%, 21.1%, and 21.1%, respectively. In the bTMB-High cohort, the lower bound of the 90% confidence interval (CI) exceeded the prespecified 5% threshold, meeting the primary endpoint. Treatment-related grade ≥3 adverse events occurred in 8.6% of patients. Early ctDNA decline at week 3 was associated with longer progression-free survival (hazard ratio 0.51, 95% CI 0.29-0.87). Baseline bTMB did not clearly distinguish responders from nonresponders, whereas higher baseline ctDNA concentrations were associated with a lower ORR.

CONCLUSIONS

Nivolumab showed activity in patients with ctDNA-defined bTMB-High cancers. Absolute bTMB alone did not reliably identify benefits, whereas baseline ctDNA concentrations and early ctDNA decline provided additional insight into response. These findings provide a preliminary signal supporting the prospective evaluation of ctDNA-based bTMB selection in a tumor-agnostic setting and warrant further validation in larger, randomized trials.

Для цитирования: Nakamura Y, Esaki T, Nishina T, Shinozaki E, Taniguchi H, Kato T, Komatsu Y, Yuki S, Kato K, Wakabayashi M, Ikeno T, Ishiguro Y, Takahashi K, Ikeda Y, Asano M, Sato A, Kuwata T, Yoshino T. Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial.. ESMO open. 2026. DOI: 10.1016/j.esmoop.2026.108578.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.